Observation on the Analgesic Effect of Bilateral Inferior Alveolar Nerve Block Combined With Parecoxib Sodium for Mandibular Orthognathic Surgery

Zhang D and Lin J*
State Key Laboratory of Oral Diseases & Department of Oral Anesthesia, Sichuan University, China

*Corresponding author: Jie Lin, State Key Laboratory of Oral Diseases & Department of Oral Anesthesia, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China, Tel: 86-28-85502116; Email: 514541402@qq.com

Abstract

Background: To compare the analgesic effect and safety of bilateral inferior alveolar nerve block combined with parecoxib sodium analgesia and simple intravenous analgesia pump in analgesia after orthognathic surgery.

Methods: Forty patients with simple ascending sagittal split osteotomy and ankle plasty were randomly divided into the experimental group and the control group, with 20 patients in each group. The experimental group received 2 ml 1% on both sides. Ropivacaine was treated with inferior alveolar nerve block anesthesia. Immediately after surgery, parecoxib sodium 40 mg was intravenously administered. The control group was given an intravenous analgesia pump for analgesia. Pain intensity (VAS pain score) and Ramsay sedation score were recorded at 2h, 4h, 8h, 24h, 48h after operation, and the incidence of postoperative adverse reactions was observed.

Results: There was no significant difference in pain intensity and Ramsay sedation score between the two groups at each time point (P>0.05). During the analgesic treatment, the incidence of nausea and vomiting (P=0.046) in the experimental group was significantly lower than that in the control group (P<0.05).

Conclusion: Bilateral inferior alveolar nerve block combined with parecoxib sodium analgesia and simple intravenous analgesia pump are effective for analgesia after mandibular orthognathic surgery, but the incidence of adverse reactions is significantly lower, more suitable for Analgesia after mandibular orthognathic surgery.

Keywords: Orthognathic surgery; Orthognathic operation of mandible; Inferior alveolar nerve; Nerve block; Postoperative analgesia; Ropivacaine; Parecoxib sodium; Nausea and vomiting

Introduction

Dentofacial deformity is a common deformity in maxillofacial surgery, and orthognathic surgery is the only treatment method. Orthognathic surgery requires the upper and lower jaws to be cut into sections, reshaped according to a predetermined model, reset and then fixed. The surgical trauma is relatively large. Due to the dense distribution of oral and maxillofacial nerves, especially the trigeminal nerve, which plays a very important role in oral and maxillofacial sensation, the pain is obvious after orthognathic surgery. Especially for orthognathic surgery involving the mandible, because the mandible is denser and contains the inferior
alveolar nerve, the third branch of the trigeminal nerve, the pain is more obvious after the mandibular orthognathic surgery [1,2]. At present, the clinical methods for postoperative analgesia after orthognathic surgery are mostly opioid-based intravenous self-controlled analgesia. Bilateral inferior alveolar nerve block combined with parecoxib sodium for postoperative analgesia is rarely reported in orthognathic surgery. The purpose of this study was to observe bilateral inferior alveolar nerve block combined with parecoxib sodium Multiple intravenous injection mode analgesia is used for the analgesic effect and safety of orthognathic surgery.

Materials and Methods

Trial design and Oversight

From February 2018 to February 2019, 40 patients in the Orthognathic Surgery Department of West China Stomatological Hospital of Sichuan University who planned to undergo mandibular sagittal splitting and genioplasty were included. All patients or their authorized agents signed informed consent. This experiment was approved by the Ethics Committee of West China Stomatological Hospital of Sichuan University.

Inclusion criteria

a) Age 18 to 45 years old, no gender limit, no brain dysfunction, able to cooperate and correctly understand Chinese, and express wishes;
b) American Association of Anesthesiologists (ASA) grade I to II.

Exclusion criteria

a) Preoperative maxillofacial neuropathological changes or maxillofacial surgery history or trauma history;
b) Long-term opioid use (daily or almost daily use of opioids for> 3 months);
c) Alcohol or drug abuse, or those who are allergic to any medications (local anesthetics) used in this study.
d) Patients with sulfa allergy or a history of cardiovascular disease. Exclusion criteria, those who failed the nerve block or failed to complete the research for various reasons.

For patients who meet the inclusion criteria, they will be visited 1 day before surgery for pain education and pain scoring training.

Randomization and Treatment

On the day of surgery, all patients underwent general anesthesia, and induced intubation with propofol 2.0 mg/kg, sufentanil 0.2 μg/kg, and cis-atracurium 0.2 mg/kg, Sufentanil 0.1 μg/kg, cis-atracurium 0.05 mg/kg, anesthesia maintenance remifentanil0.1~0.3 μg/kg/min, cis-atracurium intermittent intravenous bolus before surgery, 1%~3% Sevoflurane is continuously inhaled. Random numbers were generated using SPSS software, and the patients were randomly divided into experimental group and control group on the day of surgery, with 20 cases in each group. In the experimental group, 0.1% ropivacaine was injected into bilateral inferior alveolar nerves via sagittal splitting and suture at the end of the operation, and parecoxib sodium 40 mg was injected intravenously after the operation. The control group was connected to the intravenous analgesia pump 5 min before the end of the operation, and the loading dose was 3 mL, the background dose was 5 mL, the additional dose was 0.5 mL, and the lock time was 20 min. The analgesic pump is formulated to contain 100 μg sufentanil and 10 mg tropisetron.

Outcome Measures

Postoperatively, we evaluated and recorded the pain intensity of patients at 2, 4, 8, 24, and 48 h. If the patient did not tolerate pain, he was given an intravenous injection of parecoxib sodium 40 mg and the total amount was recorded. The number and severity of analgesia-related adverse reactions such as respiratory depression, nausea and vomiting, dizziness, skin itching, and hypotension were recorded. For pain intensity, we use the Visual Analogue Scale (VAS), 0 points for painless and 10 points for unbearable pain. The sedation score uses Ramsay sedation score: 1 is divided into restlessness and irritability; 2 is divided into quiet and cooperative; 3 is divided into lethargy and can follow instructions; 4 is divided into sleep state and can be awakened; 5 is divided into slow arousal response; 6 points Deep sleep, not awake when calling.

Statistical Analysis

The data results were analyzed by SPSS 20.0 statistical software package. The measurement data of normal distribution were expressed as mean ± standard deviation, and the comparison between groups was performed by T test. VAS scores and Ramsay scores were analyzed by anOVA with repeated measurements. Fisher exact probability method was used for counting data. Inspection level α=0.05.

Results

Patients

Among the 40 patients included, 1 patient failed the nerve block, 1 patient refused to cooperate with the completion of the experiment 24 hours after the operation and was rejected.
A total of 38 patients completed the experiment, 19 cases in each of the experimental group and the control group. There was no statistically significant difference in gender, age, and weight between the two groups (P>0.05, Table 1).

<table>
<thead>
<tr>
<th>Group</th>
<th>Gender(male/female)</th>
<th>Age</th>
<th>Weight (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test group</td>
<td>9/10</td>
<td>25.21±6.10</td>
<td>56.58±8.96</td>
</tr>
<tr>
<td>Control group</td>
<td>6/13</td>
<td>22.47±3.99</td>
<td>58.37±11.6</td>
</tr>
<tr>
<td>t</td>
<td>1.635</td>
<td>0.011</td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>0.508</td>
<td>0.62</td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Comparison of general data of two groups of patients n=19, x ±s.

**Pain Intensity and Ramsay Score**

As shown in table 2, pain intensity difference, no statistical significance between the groups (F=0.555, P=0.461), postoperative pain intensity difference was statistically significant different time points (F=48.611, P=0.000), and the interaction time and processing factors have no statistical significance (F=2.672, P=0.059), and each time point compared differences between the groups had no statistical significance (P > 0.05); There was no statistically significant difference in Ramsay scores between the two groups (F=2.885, P=0.098), there was a statistically significant difference in Ramsay scores at different postoperative time points (F=8.891, P=0.002), there was no statistically significant difference in the interaction between time and treatment factors (F=2.186, P=0.138), and there was no statistically significant difference between the two groups at each time point (P >0.05).

<table>
<thead>
<tr>
<th>Postoperative time point</th>
<th>VAS score</th>
<th>Ramsay score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Experimental group</td>
<td>Control group</td>
</tr>
<tr>
<td>2h</td>
<td>3.11±0.73</td>
<td>2.73±0.45</td>
</tr>
<tr>
<td></td>
<td>4h</td>
<td>2.89±0.80</td>
</tr>
<tr>
<td></td>
<td>8h</td>
<td>2.68±0.61</td>
</tr>
<tr>
<td></td>
<td>24h</td>
<td>1.47±0.96</td>
</tr>
<tr>
<td></td>
<td>48h</td>
<td>1.42±0.90</td>
</tr>
</tbody>
</table>

Table 2: Pain intensity and Ramsay score at each time point after operation in both groups n=19, ±s.

**Postoperative Complications and Adverse Reactions**

During the analgesia treatment, neither group of patients experienced respiratory depression, hypotension, or skin itching. The incidence of nausea and vomiting in the experimental group was 21% (4 cases), and the incidence of nausea and vomiting in the control group was 53% (10 cases). The incidence of nausea and vomiting in the experimental group was lower than that in the control group, and the difference was statistically significant (P=0.046). The incidence of dizziness in the experimental group was 11% (2 cases), and the incidence of dizziness in the control group was 26% (5 cases). There was no significant difference in the incidence of dizziness between the experimental group and the control group (P=0.202).

**Discussion**

Orthognathic surgery patients have high expectations for the operation itself, the occurrence of pain and adverse reactions is not conducive to postoperative recovery, and the comfort is reduced [3]. Some scholars have studied the use of a variety of sedatives and analgesics (including midazolam, sufentanil, analgin, tramadol, etc.) for preoperative, intraoperative, and postoperative use to control postoperative pain after orthognathic surgery. But the effect is not good [4]. In recent years, a large number of studies have reported that intraoperative nerve block anesthesia can reduce the occurrence and intensity of postoperative pain after general anesthesia [5]. The results show that the effect of nerve block...
is far better than simple analgesics [6,7]. The use of nerve block anesthesia during general anesthesia has also been reported in oral and maxillofacial surgery, and the results also show that nerve block can significantly reduce surgical incision pain after general anesthesia [8]. However, in terms of postoperative analgesia after orthognathic surgery, there are no studies that clearly report the effect of nerve block anesthesia on postoperative pain after general anesthesia for orthognathic surgery [9]. Considering that the innervation of the mandible is relatively simple, it is relatively simple to use nerve block anesthesia to control pain after mandibular surgery. Therefore, this study is to observe patients who have only mandibular orthognathic surgery.

Ropivacaine is a long-acting amide local anesthetic [10] with a lower possibility of inducing cardiovascular and neurotoxicity [11,12]. Božidar Brković et al. [13] research confirmed that ropivacaine (1%, 2 mL) is effective for postoperative analgesia after inferior alveolar nerve block and has a long duration. Ogura et al. [14] showed that 0.75% ropivacaine can effectively control pain when used for inferior alveolar nerve block during implant surgery. Chatellier et al. [15] showed that bilateral inferior alveolar nerve block reduced the incidence of nausea and vomiting after mandibular sagittal osteotomy.

Parecoxib sodium is a selective cyclooxygenase-2 (Cyclooxygenase-2 COX-2) inhibitor, by selectively inhibiting the expression of COX-2, inhibiting the production of prostaglandins to achieve analgesic effects [16,17]. Compared with non-COX-2 inhibitors, the incidence of gastrointestinal reactions is low, and it does not affect platelet aggregation and clotting time [18], and has achieved good results in postoperative analgesia of various operations.

In this study, the experimental group of patients used bilateral ropivacaine (1%, 2 mL) intraoperative inferior alveolar nerve block anesthesia, postoperative combined with parecoxib sodium multimodal analgesia, the control group used Patient controlled intravenous analgesia (sufentanil + tropisetron). The results showed that the two analgesic modes of the experimental group and the control group both had a very good analgesic effect on patients’ postoperative analgesia. The two groups of patients used the same anesthesia plan during the operation, and there was no significant difference in the amount of opioid used. Therefore, this study is to observe patients who have only mandibular orthognathic surgery.

In this study, the experimental group of patients used bilateral ropivacaine (1%, 2 mL) intraoperative inferior alveolar nerve block anesthesia, postoperative combined with parecoxib sodium multimodal analgesia, the control group used Patient controlled intravenous analgesia (sufentanil + tropisetron). The results showed that the two analgesic modes of the experimental group and the control group both had a very good analgesic effect on patients’ postoperative analgesia. The two groups of patients used the same anesthesia plan during the operation, and there was no significant difference in the amount of opioid used. Therefore, this study is to observe patients who have only mandibular orthognathic surgery.

In summary, for orthognathic patients, bilateral inferior alveolar nerve block (1% ropivacaine) combined with intravenous analgesia with parecoxib sodium has a considerable analgesic effect than simple intravenous analgesia. However, the incidence of postoperative adverse reactions is significantly lower, which is worthy of clinical application.

**Conclusion**

In summary, for orthognathic patients, bilateral inferior alveolar nerve block (1% ropivacaine) combined with intravenous analgesia with parecoxib sodium has a considerable analgesic effect than simple intravenous analgesia. However, the incidence of postoperative adverse reactions is significantly lower, which is worthy of clinical application.

**References**


